<DOC>
	<DOC>NCT00295165</DOC>
	<brief_summary>The purpose of this study is to evaluate if Leukine can induce clinical response or remission in patients with Crohn's disease.</brief_summary>
	<brief_title>Efficacy (Induction of Response/Remission) and Safety Study in Patients With Moderate to Severe Crohn's Disease</brief_title>
	<detailed_description>On 29 May 2009, Bayer began transitioning the sponsorship of this trial to Genzyme. NOTE: This study was originally posted by sponsor Berlex, Inc. Berlex, Inc. was renamed to Bayer HealthCare, Inc.</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>1. Written informed consent 2. Male or female, age &gt;/= 18 years 3. Confirmed diagnosis of Crohn's disease (endoscopic or radiological evaluation) at least 4 months prior to receiving the first dose of study drug 4. Moderately to severely active Crohn's disease at time of screening (i.e., CDAI greater than or equal to 220 and less than or equal to 475 points) 5. If under treatment for Crohn's disease, medication must be stable for at least 4 weeks prior to receiving the first dose of study drug. The following therapies are allowed: Oral therapy with salicylates (mesalamine, sulfasalazine, olsalazine, or balsalazide) for Crohn's disease Antibiotics or probiotics for Crohn's disease Topical rectal therapy with mesalamine 6. Females of childbearing potential: Negative pregnancy test within 72 hours prior to receiving the first dose of study drug 7. Sexuallyactive males and females of childbearing potential: Agreement to use adequate method of contraception throughout the study 8. Ability to selfinject study drug or availability of a designee who can do so 1. Pregnancy or breastfeeding 2. Colostomy or ileostomy 3. Immediate need for gastrointestinal (GI) surgery for active GI bleeding, peritonitis, intestinal obstruction, or intraabdominal or perianal abscess requiring surgical drainage 4. GI surgery within 6 months prior to receiving the first dose of study drug 5. Symptoms of bowel obstruction or confirmed evidence of a clinicallysignificant stricture within the last 6 months that has not been surgically corrected 6. Positive stool test results for any of the following: Bacteria: Salmonella spec. Shigella spec. Campylobacter spec. Bacterial toxin: Clostridium difficile Ova and parasites: Amoeba spec. Giardia spec. Cryptosporidium spec. 7. Any of the following laboratory abnormalities: Serum creatinine &gt;/= 2.0 mg/dL Alkaline phosphatase (AP), aspartate aminotransferase (AST), alanine aminotransferase (ALT), or total bilirubin &gt;/=; 2 x the upper limit of normal Hemoglobin (Hgb) &lt; 8.0 g/dL Absolute neutrophil count (ANC) &lt;/= 1,000 cells/µL or &gt; cells 20,000/µL 8. Planned inpatient hospitalization during the study 9. Presence or history of cancer of any type (except treated basal cell carcinoma) or definite dysplasia of the colon within the last 5 years 10. Use of any of the following medications during the specified period of time prior to receiving the first dose of study drug: At any time: Recombinant human GM CSF (sargramostim or molgramostim) Granulocyte colonystimulating factor (G CSF; filgrastim or pegfilgrastim) Natalizumab 8 weeks: or 5 halflives (whichever is longer) Licensed/registered and/or experimental antitumor necrosis factor (TNF) therapy such as infliximab or adalimumab 4 weeks: 6mercaptopurine Azathioprine Cyclophosphamide Methotrexate Mycophenolate mofetil Tacrolimus Cyclosporine Thalidomide Glucocorticoids, including budesonide and prednisone, or local glucocorticoid therapy for Crohn's disease Any other immunosuppressive drugs 11. Use of any investigational drug within 4 weeks or 5 halflives (whichever is longer) prior to receiving the first dose of study drug 12. Use of nutritional therapy (parenteral nutrition or enteral nutrition with elemental or semielemental diets) within 4 weeks prior to receiving the first dose of study drug. If the physician judges that nutritional supplementation is needed, enteral nutritional supplements will be allowed for patients who have been receiving a stable regimen for at least 4 weeks prior to receiving the first dose of study drug and that is intended to continue through the 8 week treatment period. 13. History of allergy to yeast products or to sargramostim or to any other excipient of the study drug formulation 14. Active drug or alcohol abuse 15. Clinically important comorbid conditions unrelated to Crohn's disease as determined by the investigator 16. Previous randomization into this study, or into any other study of the sponsor's sargramostim development program</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>